IRadimed Corporation — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2015; financial statements are unaudited. IRadimed develops, manufactures and sells MRI-compatible IV infusion pump systems, disposable tubing sets and related services, primarily to hospitals and acute-care facilities.
Financial performance
| Metric | Q3 2015 | Q3 2014 | Nine months 2015 | Nine months 2014 |
|---|---|---|---|---|
| Revenue | $8.19 million | $3.81 million | $22.79 million | $12.07 million |
| Gross profit / margin | $6.60 million / 80.6% | $2.85 million / 74.8% | $18.45 million / 81.0% | $9.58 million / 79.4% |
| Operating income | $3.20 million | $0.41 million | $8.16 million | $2.84 million |
| Net income | $1.87 million | $0.24 million | $5.13 million | $1.78 million |
| Diluted EPS | $0.15 | $0.02 | $0.42 | $0.18 |
- Q3 revenue grew 114.9%; management attributed growth to demand, higher pump-system sales and comparison with the 2014 domestic stop-ship period. Pump systems recognized as revenue were 248 versus 112 in Q3 2014.
- Nine-month revenue increased 88.9%. U.S. revenue rose to $21.24 million from $10.20 million, while international revenue fell to $1.56 million from $1.87 million. Nine-month pump sales were 685 versus 404.
- Nine-month operating expenses rose to $10.29 million from $6.74 million, including higher G&A, sales and marketing, and R&D. Gross margin improved, which management attributed to favorable inventory costs and sales leverage in Q3, and a greater U.S. sales mix for the nine-month period.
- Cash from operations was $5.08 million for the first nine months, versus $3.49 million. Investing activities used $0.21 million; financing activities provided $1.20 million, primarily from option exercises and related tax benefits.
- At September 30, cash and equivalents were $15.53 million and investments were $7.89 million; working capital was $27.2 million and stockholders’ equity was $28.11 million. The balance sheet reports no borrowings or other debt. Management said available cash and expected operating cash flow should cover requirements for at least 12 months.
Changes, outlook and notable items
- Compared with 2014, the business had resumed U.S. distribution of the MRidium 3860+ system in December 2014 under FDA enforcement discretion, followed by the DERS option in January 2015. The FDA Warning Letter and related 510(k) review were not resolved as of the filing; the company said it continued working with the FDA.
- Management expected continued revenue growth for the remainder of 2015, citing backlog conversion and expansion of the U.S. direct sales force. It expected operating expenses to increase due to hiring, FDA-related work, higher legal costs and additional depreciation and amortization. The filing provides no specific numerical revenue or earnings guidance.
- The company recorded a $55,433 impairment charge on patents related to certain IV sets during the first nine months. The nine-month effective tax rate was 38.4%, versus 37.5% a year earlier; management cited stock-option-related deferred tax write-offs and higher state and incentive-option taxes, partly offset by other deductions and items.
- A shareholder class action was dismissed in May 2015; the appeal was dismissed with prejudice on October 28, 2015, before the November 10 filing date. No material liability for indemnification arrangements was recorded.
- The headquarters and manufacturing facility is leased from an entity controlled by CEO Roger Susi. Remaining non-cancelable lease commitments were $1.44 million; purchase orders totaled approximately $3.24 million. Management reported effective disclosure controls and no material change in internal control over financial reporting.
Key risks
- Revenue and profitability depend heavily on the MRidium pump system and related disposables. The FDA Warning Letter, pending 510(k) review and potential regulatory restrictions, recalls or renewed shipment interruptions remain material risks.
- The company relies on multiple single-source suppliers, including the supplier of its core ultrasonic motor, and manufactures at one Florida facility.
- Other disclosed risks include dependence on GPO relationships and distributors, customer credit concentration, product liability and quality-system exposure, healthcare regulation, and reliance on the founder/CEO. The related-party facility lease is also a potential governance concern.
Important facts for investors to verify
- Subsequent FDA developments: the Warning Letter’s resolution, the 510(k) decision and any conditions affecting U.S. sales or DERS distribution.
- Whether reported backlog converts to revenue and whether pump volumes, disposable-set sales and international demand remain sustainable.
- Gross-margin durability, operating-expense growth, cash conversion and the effect of receivables growth on liquidity.
- Supplier continuity and manufacturing capacity, particularly for the single-source motor and the sole Florida facility.
- Terms and oversight of the related-party lease, and any further developments in regulatory, product-liability or other litigation matters.